Return to homepagePandemic Pact

Clinical Trails to Evaluate H5N1 Influenza Variant Vaccines

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N91019D00024-0-759102400032-1

Grant search

Key facts

  • Disease

    Influenza caused by Influenza A virus subtype H5

  • Start & end year

    2024
    2027

  • Known Financial Commitments (USD)

    $7,985,002

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    THERESA ENGEL

  • Research Location

    United States of America

  • Lead Research Institution

    LEIDOS BIOMEDICAL RESEARCH, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The current influenza H5N1 outbreak is an ongoing public health situation that has been observed in various regions throughout the US. H5N1 is a highly pathogenic avian influenza virus that primarily affects birds but can also infect other animals, including cattle (bovine H5N1). The objective of this Task Order supports NIAID's goal to conduct phase 1 and phase 2 trials on H5N1 influenza vaccines to generate data to inform decisions on which candidates to support for advanced development.